237 related articles for article (PubMed ID: 30390760)
1. Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer.
Richardson DL; Seward SM; Moore KN
Hematol Oncol Clin North Am; 2018 Dec; 32(6):1057-1071. PubMed ID: 30390760
[TBL] [Abstract][Full Text] [Related]
2. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates in Gynecologic Cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugates for ovarian cancer: current clinical development.
Stewart D; Cristea M
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
[TBL] [Abstract][Full Text] [Related]
5. Targeting Angiogenesis: Taming the Medusa of Ovarian Cancer.
Dhani NC; Oza AM
Hematol Oncol Clin North Am; 2018 Dec; 32(6):1041-1055. PubMed ID: 30390759
[TBL] [Abstract][Full Text] [Related]
6. Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer.
Fowler M
Oncology (Williston Park); 2020 Jul; 34(7):250. PubMed ID: 32674207
[TBL] [Abstract][Full Text] [Related]
7. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
Herrera AF; Molina A
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
Chu Y; Zhou X; Wang X
J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates.
Yao Y; Yu L; Su X; Wang Y; Li W; Wu Y; Cheng X; Zhang H; Wei X; Chen H; Zhang R; Gou L; Chen X; Xie Y; Zhang B; Zhang Y; Yang J; Wei Y
J Control Release; 2015 Dec; 220(Pt A):5-17. PubMed ID: 26439663
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates for cancer.
Chau CH; Steeg PS; Figg WD
Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
[TBL] [Abstract][Full Text] [Related]
12. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
[TBL] [Abstract][Full Text] [Related]
13. Unveiling the Untapped Potential of Antibody Drug Conjugates in Precision Oncology.
Trapani D; Katrini J; Curigliano G
JAMA Oncol; 2024 May; 10(5):563-564. PubMed ID: 38483383
[TBL] [Abstract][Full Text] [Related]
14. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.
Coats S; Williams M; Kebble B; Dixit R; Tseng L; Yao NS; Tice DA; Soria JC
Clin Cancer Res; 2019 Sep; 25(18):5441-5448. PubMed ID: 30979742
[TBL] [Abstract][Full Text] [Related]
16. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
Bergamini A; Ferrero S; Leone Roberti Maggiore U; Scala C; Pella F; Vellone VG; Petrone M; Rabaiotti E; Cioffi R; Candiani M; Mangili G
Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
[TBL] [Abstract][Full Text] [Related]
17. Unlocking the potential of antibody-drug conjugates for cancer therapy.
Drago JZ; Modi S; Chandarlapaty S
Nat Rev Clin Oncol; 2021 Jun; 18(6):327-344. PubMed ID: 33558752
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of ovarian cancer including immune check point inhibitor.
Kim JY; Cho CH; Song HS
Korean J Intern Med; 2017 Sep; 32(5):798-804. PubMed ID: 28823141
[TBL] [Abstract][Full Text] [Related]
19. Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
Kubizek F; Eggenreich B; Spadiut O
Protein Pept Lett; 2017; 24(8):686-695. PubMed ID: 28741467
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy before definite operative approach for women with advanced-stage epithelial ovarian cancer.
Wang PH
Taiwan J Obstet Gynecol; 2018 Oct; 57(5):623-624. PubMed ID: 30342639
[No Abstract] [Full Text] [Related]
[Next] [New Search]
